DrugRisk Adds Update Showing Increasing Yaz Settlements
Dallas, TX (PRWEB) November 05, 2013 -- The birth control safety center at DrugRisk.com is alerting those women who’ve used the contraceptives Yaz or Yasmin of new information on the site. A recent update shows the maker of the drugs has spent approximately $1.575 billion to settle lawsuits alleging they caused blood clot injuries*.
DrugRisk.com was created to give those taking popular prescription drugs the latest research, safety alerts, recalls and litigation news in one place. Patients can avoid dangerous drugs, find out if others are experiencing similar side effects and decide if they need legal advice.
The resource center has added warnings from health experts such as the British Medical Journal** and FDA*** that birth control pills containing the hormone drospirenone, like Yaz and Yasmin, can increase the risk of blood clots.
Due to the number of patients who have filed a Yaz lawsuit alleging side effects, cases were consolidated to a special federal Multi-District Litigation court in Illinois (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois)). The latest court records show 9,873 claims still pending****.
Now, DrugRisk has added information showing the maker of Yaz and Yasmin, Bayer, has spent around $1.575 billion to settle approximately 7,660 Yaz lawsuits alleging blood clot injuries like pulmonary embolism or deep vein thrombosis (DVT)*. This amounts to over $205,000 per case.
Anyone who suffered blood clots, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin is urged to contact the DrugRisk Center or speak with a lawyer about their legal options.
Due to the specialized nature of federal MDL courts, patients should seek a lawyer with experience in defective drug litigation. DrugRisk only recommends lawyers who have already settled Yaz lawsuits.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
*Bayer Stockholder’s Newsletter, Explanatory Notes; Legal Risks, 10/31/13; stockholders-newsletter-q3-2013.bayer.com/en/explanatory-notes.aspx
**BMJ, 10/25/11; ncbi.nlm.nih.gov/pubmed/22027398
***FDA, 10/27/11, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
****JPML 10/17/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-October-17-2013.pdf
Chris Schroeder, DrugNews, http://www.DrugRisk.com, 888-415-1859, [email protected]
Share this article